About Remedy Plan
Remedy Plan is a company based in Washington (United States) founded in 2011. It operates as a HealthTech. Remedy Plan has raised $24.7 million across 3 funding rounds from investors including ARE and Schooner Capital. Remedy Plan offers products and services including RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug. Remedy Plan operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Washington, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$24.7 M (USD)
in 3 rounds
-
Latest Funding Round
$18 M (USD), Series B
May 13, 2025
-
Investors
ARE
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Remedy Plan
Remedy Plan offers a comprehensive portfolio of products and services, including RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug.
A novel NAMPT inhibitor for oncology treatment is developed.
A NAMPT inhibitor for autoimmune diseases is being researched.
A NAMPT inhibitor for obesity treatment is under development.
People of Remedy Plan
Unlock access to complete
Unlock access to complete
Funding Insights of Remedy Plan
Remedy Plan has successfully raised a total of $24.7M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $18 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Remedy Plan
Remedy Plan has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE and Schooner Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed across multiple sectors.
|
Locked | Locked | Locked | |
|
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US
|
Locked | Locked | Locked |
Investor details for Remedy Plan
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Remedy Plan
Investment portfolio details for Remedy Plan
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Remedy Plan
Detailed financials for Remedy Plan
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Remedy Plan Comparisons
Peer comparison for Remedy Plan
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Remedy Plan
Remedy Plan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Remedy Plan
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Remedy Plan
Complete news archive for Remedy Plan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Remedy Plan
Remedy Plan was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Remedy Plan is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.
Remedy Plan is a funded company, having raised a total of $24.7M across 3 funding rounds to date.
Remedy Plan is engaged in the development of innovative therapeutics targeting NAMPT, a key regulator of cellular energy metabolism. The companys efforts are directed towards addressing diseases in oncology, autoimmune disorders, and metabolic conditions. A proprietary drug screening platform is utilized to discover and optimize drugs, with their lead candidate RPT1G advancing in clinical trials for oncology. Solutions are being explored to overcome historical toxicity challenges in NAMPT inhibition, offering potential treatments across multiple health sectors.
Remedy Plan's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Remedy Plan offers RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug.
Remedy Plan has 2 investors. Key investors include ARE, and Schooner Capital.